AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
Corroborated by 2 sources from 2 publishers
globalhealth4h ago
TL;DR
Reports differ across sources; according to finance.yahoo.com, april 29 (Reuters) - AbbVie on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for newer immunology drugs Skyrizi and Rinvoq, as the drugmaker continues to navigate its transition away from its once-blockbuster drug, Humira.